We are live on ! Find out more
NWBO

Northwest Biotherapeutics, Inc. Common stock
NWBO

Delisted

NWBO was delisted on the 16th of December, 2016.

Back to rankings

13 hedge funds and large institutions have $286K invested in Northwest Biotherapeutics, Inc. Common stock in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

30% more funds holding

Funds holding: 10 → 13 (+3)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

6% less capital invested

Capital invested by funds: $304K → $286K (-$17.4K)

Holders
13
Holders Change
+3
Holders Change %
+30%
% of All Funds
0.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MSAM
Moloney Securities Asset Management
Missouri
+$19.1K
2
SL
Sentinus LLC
Illinois
+$5.52K
3
KA
KLCM Advisors
Wisconsin
+$4.27K

Top Sellers

Rank Fund Capital Flow
1
WJWM
Williams Jones Wealth Management
New York
-$2.13K
Name Holding Trade Value Shares
Change 		Change in
Stake
MSAM
1
Moloney Securities Asset Management
Missouri
$181K +$19.1K +44,850 +12%
OCG
2
Opus Capital Group
Ohio
$26K – – –
MWM
3
Maripau Wealth Management
Indiana
$16.9K – – –
WJWM
4
Williams Jones Wealth Management
New York
$14.9K -$2.13K -5,000 -13%
EFG
5
Ethos Financial Group
Pennsylvania
$10K – – –
LDB
6
Lee, Danner & Bass
Tennessee
$9K +$9K +20,000 New
MCM
7
MAI Capital Management
Ohio
$8.54K – – –
AA
8
AlphaMark Advisors
Kentucky
$6K – – –
SL
9
Sentinus LLC
Illinois
$5.52K +$5.52K +12,925 New
KA
10
KLCM Advisors
Wisconsin
$4.27K +$4.27K +10,000 New
AMG
11
Advisors Management Group
Wisconsin
$4K – – –

NWBO Hedge Fund Activity: Q2 2024 in Review

13 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q2 2024, worth a combined $286K — down 5.7% from $304K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new NWBO positions and 0 closed out — a net gain of 3 holders — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Moloney Securities Asset Management, adding an estimated $19.1K. The largest seller was Williams Jones Wealth Management, cutting an estimated $2.13K.

  • 13 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q2 2024, up from 10 in Q1 2024.
  • Funds reported $286K of Northwest Biotherapeutics, Inc. Common stock stock for Q2 2024, down 5.7% quarter-over-quarter.
  • 3 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q2 2024 and 0 closed out, a net change of +3 holders.
  • The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q2 2024 was Moloney Securities Asset Management, an estimated $19.1K added.
  • The largest Northwest Biotherapeutics, Inc. Common stock seller in Q2 2024 was Williams Jones Wealth Management, an estimated $2.13K sold.

Based on aggregated 13F filings for Q2 2024.